# Michael Yu (Yu De-Chao)

Source: https://onco.cc/people/yu-michael/  
OnCo record `yu-michael` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Michael Yu founded Innovent in Suzhou in 2011 and made sintilimab one of China's best-selling cancer drugs before turning the company into a supplier of new medicines to Roche and Takeda.

## Summary

Yu earlier co-invented Oncorine (H101), the world's first approved oncolytic virus (China, 2005), and the anti-VEGF conbercept; at Innovent he built an integrated antibody company with sintilimab, four biosimilars, the CAR-T eque-cel partnership, KRAS G12C inhibitor fulzerasib and the IBI363 and IBI343 programmes licensed to Takeda in 2025.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Also known as: De-Chao Yu; 俞德超
- Tags: china
- Role: Founder, Chairman and CEO, Innovent Biologics
- Specialisms: Antibody therapeutics; Biotech leadership; Biosimilars

## Sources

- Innovent Biologics: https://www.innoventbio.com/

## Connected records

- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/)
- drugs: [Equecabtagene autoleucel](https://onco.cc/drugs/equecabtagene-autoleucel/), [Fulzerasib](https://onco.cc/drugs/fulzerasib/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/)

---
JSON: https://onco.cc/api/v1/entities/yu-michael.json